The 2023-2028 Outlook for Crohn's Disease Therapeutics in India

This study covers the latent demand outlook for Crohn's disease therapeutics across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in questio...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Crohn's Disease Drugs in India

This study covers the latent demand outlook for Crohn's disease drugs across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the ...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Critical Limb Ischemia Treatments in India

This study covers the latent demand outlook for critical limb ischemia treatments across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in qu...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Critical Infrastructure (Assets, Systems, and Networks, Physical or Virtual,) in India

This study covers the latent demand outlook for critical infrastructure (assets, systems, and networks, physical or virtual,) across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across ove...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Critical Care Diagnostics in India

This study covers the latent demand outlook for critical care diagnostics across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, ...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Critical Care Albumin Therapeutics in India

This study covers the latent demand outlook for critical care albumin therapeutics across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in q...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Critical and Chronic Care Products in India

This study covers the latent demand outlook for critical and chronic care products across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in q...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Crispbreads in India

This study covers the latent demand outlook for crispbreads across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent sh...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Crew Management Systems in India

This study covers the latent demand outlook for crew management systems across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, th...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Creamy Salad Dressings in India

This study covers the latent demand outlook for creamy salad dressings across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the...

9/14/2022 | India Outlook 2023

This study covers the latent demand outlook for Crohn's disease therapeutics across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for Crohn's disease therapeutics. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of Crohn's disease therapeutics as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AbbVie, Allergan, Astellas Pharma, Biogen, Boehringer Ingelheim, Celgene Corporation, Celltrion, Eisai Company, F. Hoffmann-La Roche, Ferring, Galapagos, Genentech, Gilead Sciences, Inc., Janssen Biotech, Johnson & Johnson, Merck & Company, Mitsubishi Tanabe Pharma, Perrigo Company, Pfizer, Salix Pharmaceuticals, Takeda Pharmaceutical Company, TiGenix, and UCB. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for Crohn's disease drugs across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for Crohn's disease drugs. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of Crohn's disease drugs as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AbbVie, Amgen, Bayer, Bristol-Myers Squibb, Eli Lilly, Ferring, Hoffman-La Roche, Pfizer, Takeda Pharmaceutical, and UCB. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for critical limb ischemia treatments across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for critical limb ischemia treatments. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of critical limb ischemia treatments as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott Laboratories, Boston Scientific Corporation, Cardiovascular Systems, Cesca Therapeutics, LimFlow, Medtronic, Micro Medical Solutions, Pluristem Therapeutics, and Rexgenero. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for critical infrastructure (assets, systems, and networks, physical or virtual,) across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for critical infrastructure (assets, systems, and networks, physical or virtual,). This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of critical infrastructure (assets, systems, and networks, physical or virtual,) as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include GE Security, Honeywell International, Inc., Quintron, Seimens, Thales Group, and WatchGuard Technologies. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for critical care diagnostics across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for critical care diagnostics. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of critical care diagnostics as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott, Alere, Bayer Healthcare, Beckman Coulter, Becton, Dickinson, Biomerieux, Bio-Rad Laboratories, Biosensors Japan, Chembio Diagnostic Systems, EKF Diagnostics, Nanomix, Nova Biomedical, Roche Diagnostics, Siemens Healthcare, and Sysmex Corporation. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for critical care albumin therapeutics across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for critical care albumin therapeutics. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of critical care albumin therapeutics as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abeona Therapeutics, ADMA Biologics, Albumedix, Asklepios Biopharmaceutical, Aspen Pharmacare Holdings, Baxter International, Bayer Healthcare, Bio Products Laboratory, Biogen, BioMarin Pharmaceutical, Biotest Pharmaceuticals, Bristol-Myers Squibb, Catalyst Biosciences, China Biologic Products Holdings, Cosmo Pharmaceuticals, CSL Behring, Grifols International, Kamada, Kedrion Biopharma, MedxBio Pte, Merck & Company, Mitsubishi Tanabe Pharma, Novo Nordisk, Octapharma, Portola Pharmaceuticals, ProMetic Life Sciences, rEVO Biologics, Rockwell Medical, Sanquin, Shanghai RAAS Blood Products Company, Shire, Teva Pharmaceutical Industries, The Medicines Company, and Ventria Bioscience. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for critical and chronic care products across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for critical and chronic care products. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of critical and chronic care products as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott, and Smiths Medical (U.K.), ConvaTec, GE Healthcare, Medtronic plc (Covidien, PLC), Mylan, Novartis, Philips Healthcare (The Netherlands), Piramal, and Plunkett’s Health Care. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for crispbreads across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for crispbreads. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of crispbreads as including all commonly understood products and/or services falling within this broad category, such as dry crisp crackers made from unsweetened dough and water that are sometimes used as a replacement for leavened bread by dieters and diabetics, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Finn Crisp and Orgran. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for crew management systems across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for crew management systems. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of crew management systems as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include ACS Systems, Inc., Advanced Optimization Systems, AIMS, ameliaCREW (U.S.), Aves One AG, AVIOLINX, Awery Aviation Solutions, Blue One Management Sa/Nv, Electronic Data Systems, Fujitsu, Hexaware (India), IBS Software, Intelisys Aviation Systems, ISA, Jeppesen, Lufthansa Systems, Maureva, PDC, Sabre Airline Solutions, and Sheorey Digital Systems Pvt. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for creamy salad dressings across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for creamy salad dressings. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of creamy salad dressings as including all commonly understood products and/or services falling within this broad category, such as ambient and chilled regular and full-fat creamy dressings intended to be eaten with fresh green salads or other raw vegetables, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Hidden Valley and Marie's. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

LATEST REPORTS

PRESS RELEASES

Use Code

SDMR20

Purchase any report

AVAIL FLAT DISCOUNT